Search results for Tremelimumab
Tremelimumab Biosimilar – Anti-CTLA4, CD152 mAb – Research Grade, ProteoGenix, PX-TA1177
Description of Tremelimumab Biosimilar - Anti-CTLA4, CD152 mAb - Research Grade General information on Anti-CTLA4/CD152(Homo sapiens) (Tremelimumab) Monoclonal Antibody Tremelimumab is studied for the treatment of Mesothelioma, Liver Neoplasms, Liver Cancer, Liver Cell Caricinoma, and HepatoCellular Carcinoma.
Host
Reactivity
Applications
Conjugation
Tremelimumab, Abbexa, abx831132
Tremelimumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting CTLA4/CD152, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Tremelimumab is under investigation for the treatment of Mesothelioma, Liver Cancer, Liver Neoplasms, Liver Cell Caricinoma, and HepatoCellular Carcinoma. Tremelimumab has been investigated in Part C: Malignant Mesothelioma and Part A and B: Advanced Solid Malignancies.
Host
Human
Reactivity
Human
Applications
ELISA, WB
Conjugation
Unconjugated
Tremelimumab ELISA Kit, ProteoGenix, KPTX196
Description of Tremelimumab ELISA Kit Tremelimumab ELISA Kit: A Comprehensive Guide Introduction Tremelimumab is a monoclonal antibody that has shown promising results in cancer immunotherapy. It targets the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), a protein that regulates the immune response and is overexpressed in many types of cancer. The Tremelimumab ELISA Kit is a powerful tool for measuring the levels of this antibody in biological samples. In this article, we will delve into the structure, activity, and applications of the Tremelimumab ELISA Kit. Structure of Tremelimumab Tremelimumab is a fully human IgG2 monoclonal antibody with a molecular weight of approximately 150 kDa. It is composed of two heavy chains and two light chains, each containing variable and constant regions. The variable regions are responsible for binding to CTLA-4, while the constant regions determine the antibody’s effector functions. Activity of Tremelimumab Tremelimumab binds to CTLA-4 with high affinity, preventing it from interacting with its ligands, CD80 and CD86. This leads to the activation of T cells, which play a crucial role in the immune response against cancer cells. By blocking CTLA-4, Tremelimumab enhances the anti-tumor activity of T cells, leading to tumor regression. Application of Tremelimumab ELISA Kit The Tremelimumab ELISA Kit is a valuable tool for measuring the levels of this antibody in various biological samples. It is commonly used in research studies to evaluate the pharmacokinetics of Tremelimumab and to monitor its levels in patients undergoing treatment. Additionally, the kit can also be used to assess the levels of Tremelimumab in preclinical models, providing valuable insights into its efficacy and safety. Measuring Tremelimumab Levels in Serum One of the main applications of the Tremelimumab ELISA Kit is to measure the levels of this antibody in serum samples. This is crucial for monitoring the response to treatment and determining the optimal dosage for each patient. The kit utilizes a sandwich ELISA method, where the Tremelimumab in the sample is captured by a specific antibody coated on the plate and then detected by a second antibody labeled with an enzyme. The intensity of the color produced is directly proportional to the amount of Tremelimumab present in the sample. Assessing Tremelimumab Levels in Tumor Tissue In addition to serum samples, the Tremelimumab ELISA Kit can also be used to measure the levels of this antibody in tumor tissue. This is particularly useful for evaluating the penetration of Tremelimumab into the tumor and its binding to CTLA-4. By measuring the levels of Tremelimumab in both serum and tumor tissue, researchers can gain a better understanding of its pharmacokinetics and mechanism of action. Detecting Anti-Drug Antibodies (ADAs) Another important application of the Tremelimumab ELISA Kit is the detection of ADAs, which are antibodies produced by the body in response to Tremelimumab treatment. These antibodies can potentially neutralize the therapeutic effects of Tremelimumab and may also lead to adverse reactions. The kit utilizes a competitive ELISA method to detect ADAs in serum samples, providing valuable information for patient safety and treatment efficacy. Conclusion The Tremelimumab ELISA Kit is a powerful tool for measuring the levels of this important antibody in various biological samples. Its high sensitivity, specificity, and ease of use make it an essential tool for researchers and clinicians working in the field of cancer immunotherapy. By providing valuable insights into the pharmacokinetics, mechanism of action, and safety of Tremelimumab, this kit contributes to the advancement of cancer treatment and brings us one step closer to a cure.
Host
Reactivity
Applications
Conjugation
Tremelimumab ELISA Kit, Abbexa, abx395085
Tremelimumab ELISA Kit is a quantitative ELISA kit for detection of Tremelimumab.Tremelimumab (CP-675,206; previously, ticilimumab) is a fully human IgG2 monoclonal antibody and has a half-life of 22 days, which was generated in a XenoMouse murine system, that has a subnanomolar affinity for binding to human cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) for treatment of patients with advanced cancers. Treatment with an anti-CTLA4 mAb prevents normal downregulation of T cells and prolongs T cell activation, thereby enhancing immune function. Generated at Abgenix (Fremont, CA) using xenomice by Pfizer, Inc. (New York), tremelimumab has been undergoing human trials for the treatment of malignant melanoma. Additionally, tremelimumab is under investigation for the treatment of Mesothelioma, Liver Cancer, Liver Neoplasms, Liver Cell Caricinoma, and HepatoCellular Carcinoma and it has been investigated in Part C: Malignant Mesothelioma and Part A and B: Advanced Solid Malignancies. Recently, it has been announced by AstraZeneca and MedImmune that tremelimumab as monotherapy does not improve survival and the primary end point is not reached (D4880C00003; NCT01843374). Further data regarding DETERMINE was presented at ASCO 2016, detailing that 571 patients were enrolled and that 81% had died throughout the duration of the study. There was no statistically significant difference between treated patients and placebo patients, and side effects such as diarrhoea, loss of appetite and development of rashes were seen at higher rates in treated patients than in placebo treatments. This indicates a need for further research into the use of tremelimumab as a monotherapy as well as use in combination therapy to potentially achieve better clinical outcomes.
Host
Reactivity
Human
Applications
ELISA
Conjugation
Tremelimumab Biosimilar - Research Grade, ichor.bio, ICH5184
Detects human CTLA-4
Host
CHO Cells
Reactivity
Human
Applications
Conjugation
Please provide the required information below so that we can quickly source your products.